International Journal of Drug Policy
Volume 12, Issue 5 , Pages 469-475, 1 November 2001

What to do about “much ado” about drug courts?

  • John F Anderson

      Affiliations

    • Corresponding Author InformationPresent address: Clinical Support Unit, 1520 Blanshard Street, 3rd Floor, Victoria, BC, Canada V8W 3C8. Tel.: +1-250-952-2301; fax: +1-250-952-3225

Department of Psychiatry, Division of Community Mental Health, Mental Health Evaluation and Community Consultation Unit, University of British Columbia, Vancouver, BC, Canada

Received 8 May 2001; accepted 10 September 2001.

Abstract 

A drug court is a mandated judicial supervision and addiction treatment alternative to incarceration for drug offenders. Enthusiasm for drug courts is high in the USA where the number of programs has expanded exponentially over the past decade in an attempt to reduce high incarceration rates for convicted drug offenders. Despite the popularity of drug courts, there is no evidence that drug court programs produce outcomes that are superior or even equal to outcomes achieved by voluntary treatment programs. Canadian drug policy should promote expansion of proven effective voluntary treatment for illicit drug misusers before endorsing unproven mandatory treatment programs, e.g. drug courts, that rely on legal coercion.

Keywords:  Drug courts, Evidence, Illicit drug abuse

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0955-3959(01)00109-8

International Journal of Drug Policy
Volume 12, Issue 5 , Pages 469-475, 1 November 2001